Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data

Three months ago, Japanese pharmaceutical giant Takeda paid a biotechnology startup $4 billion for an experimental drug in one of the largest deals of its kind in industry history. On Saturday, Takeda revealed clinical trial results that show why it was willing to write such a large check.